Zealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...

No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Roche's stock rallied in Europe, while ...

Health-care companies fell as traders rotated back into higher risk areas. Swiss drug giant Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion ...

In what it says is the biggest obesity deal to date, Zealand Pharma A/S has signed up Roche AG to a potential $5.3 billion global collaboration and license agreement to develop petrelintide, an amylin ...

Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.

The news sent Roche's stock up more than 4% in trading Wednesday, and Zealand's stock skyrocketed 40% on the news. Meanwhile, Novo Nordisk's stock was hit, sliding 4%, and Eli Lilly's stock was down ...

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class.